Free Trial

This company has been marked as potentially delisted and may not be actively trading.

ImmunoPrecise Antibodies (IPA) Stock Forecast & Price Target

ImmunoPrecise Antibodies logo
Get the Latest News and Ratings for IPA and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for ImmunoPrecise Antibodies and its competitors.

Sign Up
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

IPA Analyst Ratings Over Time

TypeCurrent Forecast
10/19/24 to 10/19/25
1 Month Ago
9/19/24 to 9/19/25
3 Months Ago
7/21/24 to 7/21/25
1 Year Ago
10/20/23 to 10/19/24
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
2 Buy rating(s)
2 Buy rating(s)
2 Buy rating(s)
2 Buy rating(s)
Hold
0 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$4.00$4.00$4.00$6.00
Forecasted UpsideN/A90.93% Upside128.57% Upside1,011.11% Upside
Consensus RatingBuyBuyBuyBuy

IPA Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

IPA Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

ImmunoPrecise Antibodies Stock vs. The Competition

TypeImmunoPrecise AntibodiesMedical CompaniesS&P 500
Consensus Rating Score
3.00
2.33
2.52
Consensus RatingBuyHoldModerate Buy
Predicted UpsideN/A1,357.67% Upside13.61% Upside
News Sentiment Rating
Neutral News

See Recent IPA News
Neutral News
Positive News
DateBrokerageAnalystActionRatingPrice TargetReport Date
Upside/Downside
Details
4/11/2025HC Wainwright
2 of 5 stars
Reiterated RatingBuy$5.00 ➝ $5.00+1,082.01%
4/1/2025Benchmark
4 of 5 stars
Reiterated RatingSpeculative Buy$3.00 ➝ $3.00+733.31%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Sunday at 04:50 PM ET.


IPA Forecast - Frequently Asked Questions

According to the research reports of 2 Wall Street equities research analysts, the average twelve-month stock price forecast for ImmunoPrecise Antibodies is $4.00, with a high forecast of $5.00 and a low forecast of $3.00.

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for ImmunoPrecise Antibodies in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" IPA shares.

According to analysts, ImmunoPrecise Antibodies's stock has a predicted upside of ∞ based on their 12-month stock forecasts.

Analysts like ImmunoPrecise Antibodies more than other "medical" companies. The consensus rating for ImmunoPrecise Antibodies is Buy while the average consensus rating for "medical" companies is Hold. Learn more on how IPA compares to other companies.


This page (NASDAQ:IPA) was last updated on 10/19/2025 by MarketBeat.com Staff
From Our Partners